Search research articles
Contact Us
Filters
Showing results (41-50 of 208) with videos related to
Page
of 21
Sort By:
British Journal of Haematology
|
February 12, 2004
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma
Joshua L Paterson, Zhihua Li, Xiao-Yan Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2008
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
Donna E Reece, Giovanni Piza Rodriguez, Christine Chen, et al.
British Journal of Haematology
|
March 16, 2004
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
Hong Chang, Stephen Sloan, Dan Li, et al.
Clinical Nuclear Medicine
|
December 22, 2025
Prognostic Value of [ 18 F]FDG PET/CT in Multiple Myeloma Patients at the Time of Initial Diagnosis
Seyed Ali Mirshahvalad, Ahmed Alghamdi, Mohammadreza Chavoshi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 9, 2003
RU486-inducible retrovirus-mediated caspase-3 overexpression is cytotoxic to bcl-xL-expressing myeloma cells in vitro and in vivo
Jonathan B Pollett, Yuan Xiao Zhu, Sonal Gandhi, et al.
Cancer Cell
|
September 14, 2013
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma
Chungyee Leung-Hagesteijn, Natalie Erdmann, Grace Cheung, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
May 26, 2018
Protocol for M<sup>3</sup>P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma
Santiago Barrio, Matteo DáVia, Laura Bruins, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
November 20, 2009
Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1
Dingyan Wang, A Keith Stewart, Lihua Zhuang, et al.
Blood
|
November 15, 2014
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
Shaji K Kumar, Betsy LaPlant, Wee Joo Chng, et al.
Clinical Lymphoma & Myeloma
|
April 14, 2009
Bortezomib in relapsed or refractory Waldenström's macroglobulinemia
Christine Chen, C Tom Kouroukis, Darrell White, et al.
Page
of 21
Search research articles
Search
Showing results (41-50 of 208) with videos related to
Sort By:
Page
of 21
British Journal of Haematology
|
February 12, 2004
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma
Joshua L Paterson, Zhihua Li, Xiao-Yan Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2008
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
Donna E Reece, Giovanni Piza Rodriguez, Christine Chen, et al.
British Journal of Haematology
|
March 16, 2004
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
Hong Chang, Stephen Sloan, Dan Li, et al.
Clinical Nuclear Medicine
|
December 22, 2025
Prognostic Value of [ 18 F]FDG PET/CT in Multiple Myeloma Patients at the Time of Initial Diagnosis
Seyed Ali Mirshahvalad, Ahmed Alghamdi, Mohammadreza Chavoshi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 9, 2003
RU486-inducible retrovirus-mediated caspase-3 overexpression is cytotoxic to bcl-xL-expressing myeloma cells in vitro and in vivo
Jonathan B Pollett, Yuan Xiao Zhu, Sonal Gandhi, et al.
Cancer Cell
|
September 14, 2013
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma
Chungyee Leung-Hagesteijn, Natalie Erdmann, Grace Cheung, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
May 26, 2018
Protocol for M<sup>3</sup>P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma
Santiago Barrio, Matteo DáVia, Laura Bruins, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
November 20, 2009
Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1
Dingyan Wang, A Keith Stewart, Lihua Zhuang, et al.
Blood
|
November 15, 2014
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
Shaji K Kumar, Betsy LaPlant, Wee Joo Chng, et al.
Clinical Lymphoma & Myeloma
|
April 14, 2009
Bortezomib in relapsed or refractory Waldenström's macroglobulinemia
Christine Chen, C Tom Kouroukis, Darrell White, et al.
Page
of 21